WO1996039148A1 - Methods and compositions for inhibiting cytomegalovirus replication - Google Patents
Methods and compositions for inhibiting cytomegalovirus replication Download PDFInfo
- Publication number
- WO1996039148A1 WO1996039148A1 PCT/US1996/008029 US9608029W WO9639148A1 WO 1996039148 A1 WO1996039148 A1 WO 1996039148A1 US 9608029 W US9608029 W US 9608029W WO 9639148 A1 WO9639148 A1 WO 9639148A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tpfa
- pfa
- tpa
- drug
- cmv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
Definitions
- the present invention relates generally to the fields of biology and medicine. More particularly, the present invention relates to compositions and methods for use in treating a mammalian patient infected with particular viruses, such as cytomegalovirus (CMV).
- viruses such as cytomegalovirus (CMV).
- HIV-1 human immunodeficiency virus
- AIDS Acquired Immune Deficiency Syndrome
- Replication of the virus is dependent on an RNA-directed DNA polymerase (reverse transcriptase; RT).
- RT reverse transcriptase
- Compounds that selectively inhibit HIV RT relative to human DNA polymerases provide a basis for anti-viral chemotherapy of pre- AIDS and AIDS patients.
- AIDS is believed to have been first observed as a medical phenomenon in the summer of 1981 in Los Angeles.
- the primary cause of ALDS is well established to be infection with HIV. It is estimated that as many as 1,000,000 persons are infected ("HIV-positive 11 ) in the USA alone.
- HIV is principally transmitted by sexual contact, IV drug use with contaminated needles, and transfusion with contaminated blood.
- the virus attacks human T4 cells, which are essential to normal function of the immune system.
- T4 cell count diminishes, loss of the immune response leads to uncontrolled bacterial, fungal, parasitic and/or viral infections, known as Opportunistic Infections (OI).
- OI Opportunistic Infections
- Chemotherapy of AIDS involves drugs directly targeting HIV, such as AZT (Zidovudine * ), and drugs targeting various opportunistic infections.
- drugs to treat any disease caused by an infectious pathogen should be effective against the target organism at reasonably low concentration (i.e., have high potency).
- CMV causes blindness in a substantial portion of AIDS patients (CMV retinitis).
- CMV retinitis AIDS patients
- Stine 1993, supra suggests that 46% of AIDS patients who have reached the latter stages of the disease suffer from CMV retinitis; other estimates range from 20% to 76% [Keijer, W. J. et al. Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Pharm World Sci 1993, 15, 56-67] and 11% to 40% [Hansen, L. L. ⁇ Retinal diseases in AIDS ⁇ . Ophthalmologe 1993, 90, 239-49].
- CMV vaccine is still in the early stages of development and antiviral agents will continue to play a major role in CMV infection management for the foreseeable future [Sasadeusz, J. J.; Sacks, S. L. Systemic antivirals in herpesvirus infections. Dermatologic Clinics 1993, 11, 171-85].
- CMV possesses a virus-specific DNA polymerase.
- Foscarnet was further shown to induce remission of CMV gastrointestinal disease in 67% of a group of AIDS patients when ganciclovir induction had failed.
- Foscarnet has been shown to penetrate the blood-brain barrier and is stated to be the drug of choice for CMV encephalitis [Hengge, U. R. et al. Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrobial Agents and Chemotherapy 1993, 37, 1010-4].
- Efforts to circumvent problems of systemic (infusion) administration of foscarnet have included transscleral iontophoresis [Sarraf, D. et al. Transscleral iontophoresis of foscarnet. American Journal of Ophthalmology 1993, 115, 748-54]; nonetheless, there remains a need for agents which may be administered in a more convenient manner, and preferably orally.
- TPFA Sodium Thiophosphonoformate, a Selective HTV RT Inhibitor: Facile Synthesis and Effects in HlV-Infected Cell Culture. Annals NY Acad. Sci. 1990, 616, 569-572].
- TPFA was found to inhibit HIV-1 reverse transcriptase with a very similar potency to that of PFA (IC 50 near 1 ⁇ M) [McKenna et al. 1990, supra].
- TPFA was significantly less inhibitory than PFA for DNA polymerases specific for Herpes simplex virus in these experiments and somewhat less inhibitory than PFA for a group of human DNA polymerases. In a comparison of TPFA vs.
- TPFA oral bioavailability of the two drugs.
- TPFA was about 3x more bioavailable than PFA when administered by SSL enteric coated capsules.
- TPFA also had a higher mean oral bioavailability, 33% (with greater variability).
- the mean oral bioavailability with TPFA was 44%, similar to that calculated from the plasma (intravenous) data.
- TPFA is demonstrated herein to be at least as effective as PFA in inhibiting CMV viral replication, while having substantially improved bioavailability relative thereto.
- Fig. 1 illustrates inhibition of hCMV replication in human cells by added TPFA and PFA Detailed Description of the Invention
- compositions and methods are provided for inhibiting CMV replication in mammalian patients using an effective amount of TPFA Because it has been reported (for example, in the aforementioned U.S. Patents 5,072,032 and 5,183,812) that TPFA was substantially less effective than PFA with respect to viruses other than HIV (e.g., herpes simplex Types I and II, Epstein-Barr, Herpes Virus 6), it is quite surprising that substantial efficacy against CMV has now been found. Given the completely unpredictable nature of the antiviral inhibitory activity of TPFA it clearly could not have been predicted that TPFA would be efficacious in the manner disclosed and claimed herein.
- viruses other than HIV e.g., herpes simplex Types I and II, Epstein-Barr, Herpes Virus 6
- TPFA and/or its addition salts may be administered to mammals (including humans) in an amount effective to inhibit viral replication.
- the optimum rate of administration for a given formulation e.g., the free compound or a physiologically acceptable salt form thereof
- mode of delivery may routinely be determined empirically.
- an effective amount of the active agent is in the range of about 1 ⁇ M to about 10 mM per kilogram of patient body weight.
- the compound may be administered orally, parenterally, topically or by other standard routes of administration; it is presently preferred to administer the compound orally.
- compositions for use in accordance with the present invention comprise a pharmaceutically acceptable carrier, adjuvant or excipient; details concerning some suitable types of formulations may be derived from, e.g., U.S. Patent 4,665,062 to Eriksson et al., the entire disclosure of which is hereby incorporated by reference.
- TPFA may suitably be administered in accordance with the present invention in conjunction with other bioactive compounds, such as AZT, ddC, ddl, antibiotics, etc.
- Preliminary experiments have compared the effects of TPFA and PFA on creatinine titers in the animal model.
- TPFA caused significant suppression of creatinine levels, which correlate with normal renal function, whereas TPFA at similar dose had little or no effect, compared to a control. This result could signify decreased kidney toxicity by TPFA vs.
- PFA TPFA has already been shown to have similar anti-HIV-1 potency to PFA but different pharmacological characteristics in animal models which indicate that TPFA might have advantages as a replacement for PFA Pursuant to the present invention, it is demonstrated that TPFA also has activity against CMV, further enhancing its potential as an AIDS-related anti- viral agent.
- TPFA (LZIII.1.19) (0.1175 g) was dissolved in pure water (HPLC Grade) and diluted to 5.00 mL (volumetric flask). Two 0.100 M solutions were prepared identically. Aliquots of each solution (2 x 3.00 mL) were employed in the CMV inhibition assay described in Example 2. The remaining solutions were stored in a freezer (-20°C), and an equivalent solution of PFA sodium salt (from Alfa products) was also prepared and used as a positive control.
- TPFA absorbs UV weakly, and PFA is undetectable by UV. Neither compound is directly detectable by emission (fluorescence) spectroscopy.
- ECD electrochemical detection
- ECD is more sensitive to changes in eluting conditions, including the eluent, than detection based on light absorption or emission.
- pH pH, ionic strength and solvent were studied for their effect on mixture resolution and detection.
- IPC Reversed-phase ion-pair chromatography
- Retention and selectivity in reversed phase IPC are influenced by a large number of experimental variables, including the type and hydrophobicity of the counterion, the concentration of ion-pairing reagent, the type and concentration of the buffer, the pH, ionic strength, concentration of organic modifier, temperature and the sorptive properties of the stationary phase.
- Solvents were of high purity (solvents, HPLC grade). For oxidative detection, removal of dissolved air from the mobile phase is necessary to prevent air bubble formation at the column outlet, which disturbs the electrolysis process. Solvents were degassed by vacuum filtration through a Versapor 450 membrane filter (0.45 ⁇ m) and argon sparging.
- the detector lost sensitivity after about one month, chiefly due to contamination of the working glassy-carbon electrode.
- Glassy-carbon working electrodes were re-activated by immersion in a solution of 1 g chromic acid in 10 mL reagent grade sulfuric acid for 15 min
- a phosphate buffer concentration of 0.1 N was used, which provides good resolution of 7-hydroxybenzoic acid (POBA - standard), TPFA and PFA in aqueous solutions.
- POBA - standard 7-hydroxybenzoic acid
- TPFA and PFA 7-hydroxybenzoic acid
- other concentrations of phosphate buffer and the organic modifier (acetonitrile) were investigated to resolve the standard, TPFA and tryptophan peaks satisfactorily.
- Optimal separation was achieved using a phosphate concentration of 0.07 N, with 7% acetonitrile.
- the concentration of tetrabutylammonium phosphate (TBAP), set at 2.4 mM significantly influenced resolution of the TPFA POBA and tryptophan peaks.
- TPFA is slowly converted to PFA in a zero order process with a half-life of >150 h.
- concentration of 1 ⁇ M HPLC analysis
- conversion of TPFA to PFA is much more rapid, but still apparently linear, possibly with some admixed non-linear component; the half-life is ca. 6 h.
- TPA TPA The metabolite was identified as a compound called thiophosphonic acid, or TPA TPA was identified in reported experiments on TPFA metabolism in dogs and cats [Straw et al. (1992), supra], TPA was shown herein to have some activity of its own, a finding which has heretofore not been reported.
- the % viral DNA replication for treated (+drug) and untreated (-drug) virus-infected cells is plotted as a function of initial drug concentration in Fig. 1.
- the positive control drug, PFA is seen to suppress viral DNA synthesis from about 0.1-1 mM, with virtually complete suppression observed at 1 mM drug.
- PFA-treated cells a similar pattern is observed, but apparently at slightly lower overall concentrations.
- Several paired points which show a variation in the replication value of ⁇ 10% or more are included; however, the data indicate that TPFA has at least comparable activity to that of PFA
- the observed activity of TPFA in Fig. 1 is probably due to a combined effect of TPFA PFA and TPA (i.e., the summed inhibitions of TPFA and its two metabolites); no attempt has been made to factor out the individual contributions to activity.
- TPFA 1 0.4810.02 0.3410.04 0.1210.02 TPA 0.0710.01 0.19 ⁇ 0.02 0.4010.02 PFA 0.3010.01 0.4310.04 0.6410.05 x10 -4 xlO -4 xlO "4 x10 "4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59536/96A AU5953696A (en) | 1995-06-06 | 1996-05-30 | Methods and compositions for inhibiting cytomegalovirus repl ication |
EP96916782A EP0831842A4 (en) | 1995-06-06 | 1996-05-30 | Methods and compositions for inhibiting cytomegalovirus replication |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46829895A | 1995-06-06 | 1995-06-06 | |
US08/468,298 | 1995-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996039148A1 true WO1996039148A1 (en) | 1996-12-12 |
Family
ID=23859244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008029 WO1996039148A1 (en) | 1995-06-06 | 1996-05-30 | Methods and compositions for inhibiting cytomegalovirus replication |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0831842A4 (en) |
AU (1) | AU5953696A (en) |
CA (1) | CA2223874A1 (en) |
WO (1) | WO1996039148A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1094821A1 (en) * | 1998-07-13 | 2001-05-02 | The University Of Southern California | Preparation and use of sulfur-containing phosphonoformate derivatives and analogs |
EP1855691A2 (en) * | 2005-03-07 | 2007-11-21 | Adventrix Pharmaceuticals, Inc. | The use of thiophosphonoformic acid and nrtis to treat viral infections |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7607496L (en) * | 1976-07-01 | 1978-01-02 | Astra Laekemedel Ab | METHOD FOR FIGHTING VIRUS INFECTIONS |
US5183812A (en) * | 1989-06-21 | 1993-02-02 | Mckenna Charles E | Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid |
US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
-
1996
- 1996-05-30 CA CA 2223874 patent/CA2223874A1/en not_active Abandoned
- 1996-05-30 EP EP96916782A patent/EP0831842A4/en not_active Withdrawn
- 1996-05-30 WO PCT/US1996/008029 patent/WO1996039148A1/en not_active Application Discontinuation
- 1996-05-30 AU AU59536/96A patent/AU5953696A/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
PHOSPHORUS, SULFUR AND SILICON, Volumes 49/50, issued 1990, McKENNA et al., "Design and Synthesis of Organophosphorus Compounds with Antiviral and Other Bioactivities", pages 183-186. * |
See also references of EP0831842A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1094821A1 (en) * | 1998-07-13 | 2001-05-02 | The University Of Southern California | Preparation and use of sulfur-containing phosphonoformate derivatives and analogs |
EP1094821A4 (en) * | 1998-07-13 | 2002-04-10 | Univ Southern California | Preparation and use of sulfur-containing phosphonoformate derivatives and analogs |
EP1855691A2 (en) * | 2005-03-07 | 2007-11-21 | Adventrix Pharmaceuticals, Inc. | The use of thiophosphonoformic acid and nrtis to treat viral infections |
EP1855691A4 (en) * | 2005-03-07 | 2010-03-31 | Adventrix Pharmaceuticals Inc | The use of thiophosphonoformic acid and nrtis to treat viral infections |
Also Published As
Publication number | Publication date |
---|---|
CA2223874A1 (en) | 1996-12-12 |
AU5953696A (en) | 1996-12-24 |
EP0831842A4 (en) | 1998-08-19 |
EP0831842A1 (en) | 1998-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6680308B1 (en) | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections | |
EP0553253B1 (en) | Proanthocyanidin polymers having antiviral activity and methods of obtaining same | |
Manoukian et al. | Rhabdomyolysis secondary to lovastatin therapy | |
EP3171886A2 (en) | Ang-(1-7) derviative oligopeptides and methods for using and producing the same | |
US20240041807A1 (en) | Combination therapy to treat urea cycle disorders | |
AU2009223064B2 (en) | Use of 4'-Thio-2'-Deoxynucleosides as Anti Orthopoxvirus Agents | |
EP0313654B1 (en) | Drug for prophylaxis and treatment of hepatopathy | |
Hostetler et al. | Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro | |
WO1996039148A1 (en) | Methods and compositions for inhibiting cytomegalovirus replication | |
AU3043300A (en) | Use of bisphosphonates for the prevention and treatment of infectious processes | |
CN101094681A (en) | Dialysates and methods and systems related thereto | |
US5254587A (en) | Methods for treating AIDS | |
US20230143813A1 (en) | Use of Ovatodiolide against SARS-CoV-2 | |
EP0255420B1 (en) | Antiviral agent for inhibiting growth of virus of acquired immune deficiency syndrome (aids) | |
WO1990003172A2 (en) | Bile acids for treatment of viral infections | |
US5089508A (en) | Methods for treating aids | |
WO2012064222A1 (en) | Agent for inducing endogenous interferon | |
US6172119B1 (en) | Method of treating acute renal failure | |
WO2007089562A2 (en) | Compositions and methods for the treatment of viral infections | |
US6197831B1 (en) | Method of treating septic shock | |
Soike et al. | Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-β | |
AU3720593A (en) | Ion pairs of hypericin compounds having antiviral activity | |
EP0082667A1 (en) | Pharmaceutical compositions | |
US5185366A (en) | Method for treatment and prevention of diseases caused by enveloped viruses, including herpes simplex virus types 1 and 2 diseases, using 3,4-dihydroxy-2H-benzopyran-2H-one | |
RU2333753C1 (en) | Antiviral medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2223874 Country of ref document: CA Ref country code: CA Ref document number: 2223874 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996916782 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996916782 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996916782 Country of ref document: EP |